Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denintuzumab mafodotin + rituximab + ifosfamide + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination regimen composed of **denintuzumab mafodotin** (an antibody-drug conjugate targeting CD19), **rituximab** (an anti-CD20 monoclonal antibody), **ifosfamide**, **carboplatin**, and **etoposide** (all cytotoxic chemotherapy agents) designed to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin lymphomas. Denintuzumab mafodotin acts by selectively delivering a cytotoxic agent to CD19-expressing B cells, while rituximab mediates B-cell depletion through CD20 targeting. The remaining agents are DNA-damaging cytotoxics. The combination exploits non-overlapping mechanisms for B-cell malignancies and is intended to increase efficacy compared to traditional regimens[3][5]. Denintuzumab mafodotin was developed by Seagen.
- Other names
- denintuzumab mafodotin + R-ICEdenintuzumab mafodotin + rituximab + ICE
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on denintuzumab mafodotin + rituximab + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denintuzumab mafodotin + rituximab + ifosfamide + carboplatin + etoposide.